LIGAND PHARMACEUTICALS INC — Director's Dealing 2021

Jan 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-01-25

Reporting Person: Korenberg Matthew E (EVP,Finance & Strategy and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-25	Common Stock	A	2305	$0.0	Acquired	28241	Direct
2021-01-25	Common Stock	F	671	$156.01	Disposed	27570	Direct
2021-01-25	Common Stock	A	4803	$0.0	Acquired	32373	Direct
2021-01-25	Common Stock	F	1440	$156.01	Disposed	30933	Direct

Footnotes

F1: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.

F2: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs.

F3: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.